Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, and markets ...

While hiring activity has not yet picked up, it should do so soon, according to BioSpace Recruitment Manager Greg Clouse.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Novo Nordisk (NVO – Research Report) and Veeva Systems (VEEV ...

AI names and growth stocks have stumbled in early 2025. 2024’s big stock market winners are among the worst performers in recent weeks. AI stocks have plunged double digits amid a wave of challenging ...

Bristol Myers Squibb is axing another 280 jobs as part of its $1.5 billion cost-cutting plan. The company is laying off 223 ...

A Peninsula company that makes medical devices for body sculpting, tattoo removal, acne and more hopes to go private and ...

MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025.

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

With proper data governance, the pharma industry can improve patient-centricity in trials and bring lifesaving therapies to ...

With annual US sales of $1.81 billion, as per IQVIA MAT data (January 2025), this approval marks a significant milestone for Zydus. The company will manufacture Dasatinib at its Ahmedabad SEZ facility ...

We recently published a list of 25 Best Dividend Stocks to Buy According to Billionaires. In this article, we are going to ...

Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...